Funded Biomarker Testing
26 items
1p/19q, CDKN2A testing should be performed on patients who test positive for an IDH1 mutation.
Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: 1p/19q, CDKN2A
Testing Method:Single Nucleotide Polymorphism (SNP)
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network
For IDH Wild-Type patients diagnosed with Grade II and III tumours, sequencing should be performed.
Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: +7/-10
Testing Method:Single Nucleotide Polymorphism (SNP)
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network
For IDH wild-type patients diagnosed with Grade II and III tumours, sequencing should be performed.
Funded Biomarker Disease Site:
Biomarker: EGFR, IDH, TERT
Testing Method:Sequencing
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network
H3-K27M testing should be performed on patients diagnosed with a glioma tumour in the midline location.
Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: H3-K27M
Testing Method:Immunohistochemistry (IHC)
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network
MGMT testing should be performed on all Grade IV patients > 55, all Grade III patients >55 and IDH wild-type Grade III patients ≤ 55.
Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: MGMT Methylation
Testing Method:Methylation
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network
Reflex testing for the diagnosis of serous tumours (epithelial ovarian, fallopian tube, peritoneal cancers) when needed to establish histologic subtype.
Funded Biomarker Disease Site: Ovary
Biomarker: p53, WT1
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North Bay Regional Health Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on all newly diagnosed breast cancers.
Funded Biomarker Disease Site: Breast
Biomarker: HER2, ER, PR
Testing Method:Immunohistochemistry (IHC)
Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital
Reflex testing on all newly diagnosed breast cancers.
Funded Biomarker Disease Site: Breast
Biomarker: HER2
Testing Method:In Situ Hybridization (ISH)
Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital
Reflex testing on all newly diagnosed ductal carcinoma in situ (DCIS).
Funded Biomarker Disease Site: Breast
Biomarker: ER
Testing Method:Immunohistochemistry (IHC)
Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital
Reflex testing on cases of adult patients with persistent, recurrent, or metastatic cervical cancer when treatment is being considered
Funded Biomarker Disease Site: Cervix
Biomarker: PD-L1 (CPS ≥1)
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed epithelial and low malignant potential ovarian tumours.
Funded Biomarker Disease Site: Ovary
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed gastric tumours when EBV associated adenocarcinoma is being considered.
Funded Biomarker Disease Site: Stomach
Biomarker: EBER
Testing Method:In Situ Hybridization (ISH)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System